Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Restructuring Costs (2024 - 2025)

Monte Rosa Therapeutics' Restructuring Costs history spans 2 years, with the latest figure at $9.2 million for Q4 2025.

  • For Q4 2025, Restructuring Costs rose 18.95% year-over-year to $9.2 million; the TTM value through Dec 2025 reached $33.9 million, up 14.29%, while the annual FY2025 figure was $33.9 million, 14.3% up from the prior year.
  • Restructuring Costs reached $9.2 million in Q4 2025 per GLUE's latest filing, up from $8.6 million in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $9.2 million in Q4 2025 to a low of $6.8 million in Q1 2024.